From Dividend.com | Health care products maker Abbott Laboratories saw its rating cut on Monday by analysts at Goldman Sachs. The firm lowered its rating on ABT to “Neutral” from “Buy,” but maintained its $69 price target on the stock. That target represents a more than 48% upside to Abbott’s Friday closing price of $46.53.

Get the full story: dividend.com.